Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

J & J Ending Run of Infant Acetaminophen Drops

By Drug Discovery Trends Editor | May 5, 2011

WASHINGTON (AP) – Johnson & Johnson and other makers of cold and fever medications said that they will discontinue infant drops of medicines containing acetaminophen in an effort to avoid confusion that can lead to dangerous overdoses.

The industry association for over-the-counter medicine companies said its members will begin phasing out the liquid drops later this year.

After the transition is complete, companies will only sell a single formula for all children under the age of 12. Currently, J&J and other companies market infant formulations that contain half the amount of acetaminophen as that found in regular children’s formula.

Acetaminophen is a ubiquitous pain reliever and fever reducer found in Tylenol, Nyquil and thousands of other medicines used to treat flu, headache and sore throat. While generally safe when used as directed, acetaminophen is the leading cause of liver failure in the U.S. and overdoses send more than 50,000 people to emergency rooms each year.

The announcement late Wednesday appeared timed to head off debate about the products at a Food and Drug Administration meeting scheduled for later this month. The FDA has called the meeting to discuss whether additional instructions and safety labeling are needed when acetaminophen products are used in children younger than 2.

The infant products now on the market usually come with a dropper and are designed to deliver 80 milligrams of acetaminophen per 0.8 milliliter of liquid.

Beginning mid-year, drugmakers will stop producing those formulas and only the standard children’s formula, which contains 160 milligrams per 5 milliliter. Parents can accidentally give infants too much of the ingredient if they do not read the instructions carefully or use the dropper with a different formulation of the drug.

“We are committed to providing parents and caregivers with the tools and information they need to help give their children the right amount of these medicines,” said Scott Melville, president of the Consumer Healthcare Products Association. Member companies include J&J, Novartis, Procter & Gamble and makers of generic cold medicines.

The elimination of acetaminophen-based infant formula marks the second time the drug industry has pulled its products off the market ahead of federal action. In 2007, the same industry group announced it would discontinue all infant decongestant medicines, ahead of an FDA meeting to look into deaths with the products.

Date: May 4, 2011
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50